This is a preview of subscription content, log in via an institution to check access.
Notes
The clinical trial was supported by Bristol-Myers-Squibb and Pfizer, Inc.
Reference
Glickman A, et al. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery. Gynecologic Oncology : 25 Aug 2020. Available from: URL: http://doi.org/10.1016/j.ygyno.2020.07.096
Rights and permissions
About this article
Cite this article
Apixaban high value for thromboprophylaxis after gynaecologic surgery. PharmacoEcon Outcomes News 862, 1 (2020). https://doi.org/10.1007/s40274-020-7119-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7119-4